TEXAS BIOMEDICAL RESEARCH INSTITUTE
Balance Sheet
Fiscal Year Start:
Jan 1
Assets in 2024 (Year End)
$366,564,882
Other Assets
34%
Property, Plant, & Equipment (net)
31%
Investments
26%
Receivables (Non-Related)
5%
Cash & Equivalents
2%
Prepaid Expenses
2%
Related-Party Receivables
0%
Inventories
0%
Liabilities in 2024 (Year End)
$224,671,517
Tax-Exempt Bond Liabilities
61%
Notes Payable / Debt (Non-Related)
23%
Payables & Accruals
16%
Deferred Revenue
<1%
Other Liabilities
<1%
Grants Payable
0%
Custodial & Escrow Liabilities
0%
Related-Party Payables
0%
Assets
2023
2024
Change
Cash & Equivalents
$14,149,043
$8,982,154
-37%
Receivables (Non-Related)
$15,951,425
$18,013,175
+13%
Related-Party Receivables
-
-
-
Inventories
-
-
-
Prepaid Expenses
$6,634,142
$5,583,701
-16%
Investments
$101,669,205
$93,548,459
-8%
Property, Plant, & Equipment (net)
$102,272,449
$115,169,181
+13%
Other Assets
$6,002,314
$125,268,212
+1987%
Total Assets
$246,678,578
$366,564,882
+49%
Liabilities
2023
2024
Change
Payables & Accruals
$29,477,758
$34,840,112
+18%
Grants Payable
-
-
-
Deferred Revenue
$1,406,944
$1,679,173
+19%
Tax-Exempt Bond Liabilities
$34,182,005
$136,447,531
+299%
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
$30,052,856
$51,661,614
+72%
Related-Party Payables
-
-
-
Other Liabilities
$529,573
$43,087
-92%
Total Liabilities
$95,649,136
$224,671,517
+135%
Net assets
2023
2024
Change
Restricted Net Assets
$50,538,769
$49,907,582
-1%
Unrestricted Net Assets
$100,490,673
$91,985,783
-8%
Net assets
2023
2024
Change
Net assets
+$151,029,442
+$141,893,365
-6%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)